Overview

Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer

Status:
Active, not recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

To test whether cetuximab improves efficacy/tolerance as compared to methotrexate in first line treatment of unfit patients ³ 70 years old with recurrent and /or metastatic HNSCC. Efficacy assessed by failure free survival

Phase:

Phase 3

Details

Lead Sponsor:

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators:

Ligue contre le cancer, France
Merck Serono International SA
National Cancer Institute, France

Treatments:

Cetuximab
Methotrexate